This finding may evoke a hypothesis that the dual use of finerenone and SGLT2 inhibitors have additive cardiorenal benefits in patients with T2D and CKD, and an exploratory study testing such hypothesis is ongoing (CONFIDENCE: NCT05254002). The gene discussed is SLC5A2; the disease is chronic kidney disease.